Adaptin Bio (APTN) Net Income towards Common Stockholders Growth (1y) (2024 - 2026)
Powered by 
Analysis
Adaptin Bio (APTN) Net Income towards Common Stockholders Growth (1y) (2024 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 42.87% |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 57.65% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 162.64% |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | -102.48% |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 521.17% |
| 10 | Adaptin Bio | 56.76 Mn | 56.09 Mn | - | 20.75% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 20.75% |
| Mar 31, 2026 | -90.04% |
| Dec 31, 2025 | -63.44% |
| Sep 30, 2025 | -51.29% |
| Jun 30, 2025 | -85.76% |
| Mar 31, 2025 | -77.67% |
| Dec 31, 2024 | -2,408.67% |
| Sep 30, 2024 | -2,479.42% |